An increasing number of reports highlight the potential of machine learning (ML) methodologies over the conventional generalised linear model (GLM) for non-life insurance pricing. In parallel, national and international regulatory institutions are accentuating their focus on pricing fairness to quantify and mitigate algorithmic differences and discrimination. However, comprehensive studies that assess both pricing accuracy and fairness remain scarce. We propose a benchmark of the GLM against mainstream regularised linear models and tree-based ensemble models under two popular distribution modelling strategies (Poisson-gamma and Tweedie), with respect to key criteria including estimation bias, deviance, risk differentiation, competitiveness, loss ratios, discrimination and fairness. Pricing performance and fairness were assessed simultaneously on the same samples of premium estimates for GLM and ML models. The models were compared on two open-access motor insurance datasets, each with a different type of cover (fully comprehensive and third-party liability). While no single ML model outperformed across both pricing and discrimination metrics, the GLM significantly underperformed for most. The results indicate that ML may be considered a realistic and reasonable alternative to current practices. We advocate that benchmarking exercises for risk prediction models should be carried out to assess both pricing accuracy and fairness for any given portfolio.

This paper presents an actuarially oriented approach for estimating health state utility values using an enhanced EQ-5D-5L framework that incorporates demographic heterogeneity directly into a Generalised Linear Model (GLM). Using data from 148 patients with Stage IV non-small cell lung cancer (NSCLC) in South Africa, an inverse Gaussian GLM was fitted with demographic variables and EQ-5D-5L domain responses to explain variation in visual analogue scale (VAS) scores. Model selection relied on Akaike Information Criterion, Bayesian Information Criterion, and residual deviance, and extensive diagnostic checks confirmed good calibration, no overdispersion, and strong robustness under bootstrap validation. The final model identified age, gender, home language, and financial dependency as significant predictors of perceived health, demonstrating that utility values differ meaningfully across demographic groups. By generating subgroup-specific estimates rather than relying on uniform value sets, the framework supports more context-sensitive cost-effectiveness modelling and fairer resource allocation. Although developed in the South African NSCLC setting, the methodology is generalisable and offers actuaries and health economists a replicable tool for integrating population heterogeneity into Health Technology Assessment, pricing analysis, and value-based care.

Longevity risk significantly impacts the reserve adequacy ratio of annuity issuers, thereby reducing product profitability. Effectively managing this risk has thus become a priority for insurance companies. A natural hedging strategy, which involves balancing longevity risk through an optimised portfolio of life insurance and annuity products, offers a promising solution and has attracted considerable academic attention in recent years. In this study, we construct a realistic portfolio scenario comprising annuities and life insurance policies across various ages and genders. By applying Cholesky decomposition, we transform the portfolio into an uncorrelated linear model. Our objective function minimises the variance in portfolio value changes, allowing us to explore the impact of mortality on longevity risk mitigation through natural hedging. Using actuarial mathematics and the Bayesian MCMC algorithm, we analyse the factors influencing the hedging effectiveness of a portfolio with minimised variance. Empirical findings indicate that the optimal life-to-annuity ratio is influenced by multiple factors, including gender, age, projection period, and forecast horizon. Based on these findings, we recommend that insurance companies adjust their business structures and actively pursue product innovation to enhance longevity risk management.